TeraWulf
WULF
Bitdeer Technologies
BTDR
Riot Platforms
RIOT
Bitfarms
BITF
Strategy
MSTR
US Stock MarketDetailed Quotes
GRCE Grace Therapeutics
- 3.030
- +0.010+0.33%
Close Feb 28 16:00 ET
- 3.030
- 0.0000.00%
Post 20:01 ET
40.65MMarket Cap-2.63P/E (TTM)
3.100High2.889Low13.12KVolume2.930Open3.020Pre Close39.71KTurnover0.15%Turnover RatioLossP/E (Static)13.42MShares4.96552wk High0.78P/B25.78MFloat Cap2.12652wk Low--Dividend TTM8.51MShs Float2016.000Historical High--Div YieldTTM6.98%Amplitude1.720Historical Low3.027Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Grace Therapeutics Stock Forum
Stock Market News Today
Dow Jones· 6 mins ago
Grace's GTx-104 Clinical Data Reveals Major Breakthrough for Brain Hemorrhage Treatment
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Monday, 10th February at 8:01 am
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine
New Drug Application (NDA) Submission Expected in the First Half of 2025
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ: GRCE), formerly Acasti Pharma Inc. (Grace Therapeut...
No comment yet